<unk>  is the<unk> ommercial name of the polysaccharide vaccine against the bacterium (specifically serogroups A,<unk> , Y, and<unk> -135) that<unk> auses meningococcal meningitis. The product, by JN-International Medical<unk> orporation, is designed and formulated to be used in developing<unk> ountries for protecting populations during meningitis disease epidemics. Meningococcal meningitis is a bacterial infection<unk> aused by the bacterium Neisseria meningitidis, also known as meningococcus. The vaccine is made from bacterial<unk> apsular polysaccharides through fermentation of each individual serogroup of Neisseria meningitidis in bioreactors. After fermentation, the polysaccharides are purified, formulated, and lyophilized using preservatives and stabilizers to make a vaccine product. The vaccine<unk> annot protect from other serogroups of N. meningitidis and<unk> annot eliminate the<unk> hance of infection by these serogroups.
NmVac4-A/C/Y/W-135
RUB A535
NDV-HXP-S
Kozak consensus sequence
H3S10P
H3K9me2
H3K9me3
H3K36me